Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Metabolic Neuropathy Workup

  • Author: Tarakad S Ramachandran, MBBS, MBA, MPH, FAAN, FACP, FAHA, FRCP, FRCPC, FRS, LRCP, MRCP, MRCS; Chief Editor: Nicholas Lorenzo, MD, MHA, CPE  more...
 
Updated: Oct 27, 2014
 

Laboratory Studies

See the list below:

  • General laboratory tests for metabolic neuropathy
    • Blood glucose, glucose tolerance test and glycosylated hemoglobin levels, vitamin B-12, folate, vitamin E, cryoglobulins, hepatitis profile, and antibodies to antinuclear antigen (ANA), extractable nuclear antigen (ENA), and sulfatide
    • Creatinine
    • Thyroid function tests
    • Liver function tests
    • Serum protein electrophoresis or serum immunofixation, anti-MAG antibodies
  • Suggested studies for disorders of carbohydrate metabolism (when metabolic myopathy is being ruled out)
    • Ischemic forearm exercise test
    • Serum lactate, ammonia, and pyruvate
    • Urine myoglobin
    • Muscle histochemistry
    • Enzyme assays of muscle, blood, and fibroblast
    • Leukocyte glycogen levels to detect acid maltase deficiency
    • Leukocyte, DNA analyses (McArdle disease)
  • Suggested investigations for mitochondrial disorders
    • Resting lactate and pyruvate level
    • Muscle histochemistry and electron microscopy
    • Serum mitochondrial DNA deletion and mutation
    • Enzyme assays of muscle, platelets, liver, and fibroblasts
    • Muscle cytochrome oxidase analysis
  • Other suggested studies
    • Biotinidase levels
    • Aminolevulinic acid synthase in urine (porphyria)
    • Arylsulfatase A and B (leukodystrophies)
    • Hexosaminidases
    • Urine oxalate levels to rule out primary hyperoxaluria, which in patients who are undergoing hemodialysis may present with peripheral neuropathy (direct deposition of oxalate crystals on Schwann cells)
Next

Imaging Studies

See the list below:

  • Peripheral nerve imaging: Magnetic resonance techniques have demonstrated increased water content in peripheral nerves of patients with diabetes. Its utility remains under investigation. Magnetic resonance imaging and ultrasound can be used in peripheral nerve imaging to demonstrate extrinsic compressive lesions, focal neural lesions such as neural edema and swelling, focal neural scarring (posttraumatic neuroma in continuity) and intraneural ganglia. Ultrasound can be particularly useful in assessing for intrinsic lesions in small peripheral nerves because of the superior spatial resolution of ultrasound in assessing superficial structures. Plain radiography (and sometimes computed tomography scanning) may show significant bone changes and should be the initial imaging modality.[18]
  • Acute or subacute denervation results in prolonged T2 relaxation time, producing increased signal in skeletal muscle on short tau inversion-recovery and fat-suppressed T2-weighted images. Chronic denervation produces fatty atrophy of skeletal muscles, resulting in increased muscle signal on T1-weighted images.[19]
  • When metabolic myopathy is being ruled out, phosphorus magnetic resonance spectroscopy of muscle may be useful for the investigation of carbohydrate metabolism (McArdle disease, phosphofructokinase deficiency) and mitochondrial disorders.
  • MRI of the brain is suggested for patients in whom leukodystrophies are suspected.
Previous
Next

Other Tests

See the list below:

  • Nerve conduction studies (NCS) and electromyography (EMG) are essential to classify and determine the severity of any neuropathy
    • NCS abnormalities in axonal sensory or sensory motor polyneuropathies consist of small or absent sensory nerve action potentials and compound motor action potentials, but NCS findings may be normal in mild cases or in small-fiber neuropathies. NCS abnormalities in demyelinating polyneuropathies can include prolonged distal and F-wave latencies, decreased conduction velocities, and conduction block.
    • EMG abnormalities are more common in axonal neuropathies and consist of signs of denervation (fibrillations and positive sharp waves and reduced recruitment patterns) and reinnervation (large-amplitude, broad-duration polyphasic motor unit potentials).
  • Quantitative sensory testing (QST): Perform QST to evaluate involvement of small nerve fibers. QST holds promise in metabolic neuropathies as a technique to assess perceptual thresholds to pain, temperature, or vibration.
  • Quantitative sudomotor axonal reflex testing (Q-SART) is very useful to identify autonomic involvement and help in establishing the prognosis.
  • Measurement of nerve excitability by threshold tracking provides complementary information to conventional nerve conduction studies and may be used to infer the activity of a variety of ion channels, energy-dependent pumps, and ion exchange processes activated during the process of impulse conduction. This review highlights recent clinical excitability studies that have suggested mechanisms for nerve involvement in a range of metabolic and toxic neuropathies. While there is growing evidence of their utility to provide novel insights into the pathophysiological mechanisms involved in a variety of neuropathic disturbances, it is too early to know whether they have diagnostic value.[21]
Previous
Next

Procedures

See the list below:

  • Sural nerve biopsy in diabetic neuropathy may reveal a histologic pattern suggestive of nerve ischemia (selective fascicular involvement, diffuse loss of myelinated fibers). However, sural nerve biopsy rarely is performed now unless evidence is being sought of vasculitic, demyelinating, hereditary, or infectious origin for the neuropathy. Muscle biopsy should always be done with nerve biopsy to increase the diagnostic yield for vasculitic and amyloid neuropathies.
  • Punch skin biopsy and immunohistochemical staining for peripheral nerve axons can be performed.
    • Advances in immunohistochemical techniques, specifically the development of antibodies to human protein gene product 9.5 (PGP 9.5), an antigen present in peripheral nerve fibers of all calibers, allow assessment of the effect of diseases on peripheral nerve density.
    • Fiber density can be quantified with an interobserver agreement of 96%. Reports exist of excellent correlation between reductions in intradermal nerve fiber density and severity of symptoms in a wide range of neuropathies.
Previous
Next

Histologic Findings

Loss of myelinated fibers, epineurial periarteriolar lymphocytic infiltrates, and selective involvement of fascicles can be observed in diabetic radiculoplexopathy or other vasculitic neuropathies. Amyloid birefringent deposits (under polarized light) within the endoneurium are revealed in amyloid neuropathy.

Previous
 
 
Contributor Information and Disclosures
Author

Tarakad S Ramachandran, MBBS, MBA, MPH, FAAN, FACP, FAHA, FRCP, FRCPC, FRS, LRCP, MRCP, MRCS Professor Emeritus of Neurology and Psychiatry, Clinical Professor of Medicine, Clinical Professor of Family Medicine, Clinical Professor of Neurosurgery, State University of New York Upstate Medical University; Neuroscience Director, Department of Neurology, Crouse Irving Memorial Hospital

Tarakad S Ramachandran, MBBS, MBA, MPH, FAAN, FACP, FAHA, FRCP, FRCPC, FRS, LRCP, MRCP, MRCS is a member of the following medical societies: American College of International Physicians, American Heart Association, American Stroke Association, American Academy of Neurology, American Academy of Pain Medicine, American College of Forensic Examiners Institute, National Association of Managed Care Physicians, American College of Physicians, Royal College of Physicians, Royal College of Physicians and Surgeons of Canada, Royal College of Surgeons of England, Royal Society of Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Glenn Lopate, MD Associate Professor, Department of Neurology, Division of Neuromuscular Diseases, Washington University School of Medicine; Consulting Staff, Department of Neurology, Barnes-Jewish Hospital

Glenn Lopate, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, Phi Beta Kappa

Disclosure: Nothing to disclose.

Chief Editor

Nicholas Lorenzo, MD, MHA, CPE Founding Editor-in-Chief, eMedicine Neurology; Founder and CEO/CMO, PHLT Consultants; Chief Medical Officer, MeMD Inc

Nicholas Lorenzo, MD, MHA, CPE is a member of the following medical societies: Alpha Omega Alpha, American Association for Physician Leadership, American Academy of Neurology

Disclosure: Nothing to disclose.

Additional Contributors

Milind J Kothari, DO Professor, Department of Neurology, Pennsylvania State University College of Medicine; Consulting Staff, Department of Neurology, Penn State Milton S Hershey Medical Center

Milind J Kothari, DO is a member of the following medical societies: American Academy of Neurology, American Neurological Association, American Association of Neuromuscular and Electrodiagnostic Medicine

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous authors, Fernando Dangond, MD, and Luis Carlos Sanin, MD, to the development and writing of this article.

References
  1. Tamborlane WV, Ahern J. Implications and results of the Diabetes Control and Complications Trial. Pediatr Clin North Am. 1997 Apr. 44(2):285-300. [Medline].

  2. Pop-Busui R, Herman WH, Feldman EL, Low PA, Martin CL, Cleary PA, et al. DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep. 2010 Aug. 10(4):276-82. [Medline].

  3. Greene DA, Stevens MJ, Feldman EL. Diabetic neuropathy: scope of the syndrome. Am J Med. 1999 Aug 30. 107(2B):2S-8S. [Medline].

  4. Voulgari C, Psallas M, Kokkinos A, Argiana V, Katsilambros N, Tentolouris N. The association between cardiac autonomic neuropathy with metabolic and other factors in subjects with type 1 and type 2 diabetes. J Diabetes Complications. 2011 May-Jun. 25(3):159-67. [Medline].

  5. Stirban A. Microvascular dysfunction in the context of diabetic neuropathy. Curr Diab Rep. 2014 Nov. 14(11):541. [Medline].

  6. Dyck PJ, Norell JE, Dyck PJ. Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy. Neurology. 1999 Dec 10. 53(9):2113-21. [Medline].

  7. Harati Y. Frequently asked questions about diabetic peripheral neuropathies. Neurol Clin. 1992 Aug. 10(3):783-807. [Medline].

  8. Pirart J. [Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (3rd and last part) (author's transl)]. Diabete Metab. 1977 Dec. 3(4):245-56. [Medline].

  9. Arezzo JC. New developments in the diagnosis of diabetic neuropathy. Am J Med. 1999 Aug 30. 107(2B):9S-16S. [Medline].

  10. Chalk CH. Acquired peripheral neuropathy. Neurol Clin. 1997 Aug. 15(3):501-28. [Medline].

  11. Dick PJ, Thomas PK, eds. Peripheral Neuropathy. 3rd ed. Philadelphia: WB Saunders Co; 1993.

  12. Comi G, Corbo M. Metabolic neuropathies. Curr Opin Neurol. 1998 Oct. 11(5):523-9. [Medline].

  13. Thomas PK, Tomlinson DR. Diabetic and hypoglycemic neuropathy. Dick PJ, Thomas PK, eds. Peripheral Neuropathy. Philadelphia: WB Saunders Co; 1993. 1221.

  14. Apfel SC. Neurotrophic factors in the therapy of diabetic neuropathy. Am J Med. 1999 Aug 30. 107(2B):34S-42S. [Medline].

  15. Misiunas A, Niepomniszcze H, Ravera B, et al. Peripheral neuropathy in subclinical hypothyroidism. Thyroid. 1995 Aug. 5(4):283-6. [Medline].

  16. Kyle RA. Monoclonal proteins in neuropathy. Neurol Clin. 1992 Aug. 10(3):713-34. [Medline].

  17. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006 Mar 9. 354(10):1021-30. [Medline].

  18. Simmons DN, Lisle DA, Linklater JM. Imaging of Peripheral Nerve Lesions in the Lower Limb. Techniques in Foot & Ankle Surgery. 2008/12. 7(4):224-237.

  19. Lisle DA, Johnstone SA. Usefulness of muscle denervation as an MRI sign of peripheral nerve pathology. Australas Radiol. 2007 Dec. 51(6):516-26. [Medline].

  20. Burn DJ, Bates D. Neurology and the kidney. J Neurol Neurosurg Psychiatry. 1998 Dec. 65(6):810-21. [Medline].

  21. Krishnan AV, Lin CS, Park SB, Kiernan MC. Assessment of nerve excitability in toxic and metabolic neuropathies. J Peripher Nerv Syst. 2008 Mar. 13(1):7-26. [Medline].

  22. Callaghan B, Feldman E. The metabolic syndrome and neuropathy: therapeutic challenges and opportunities. Ann Neurol. 2013 Sep. 74(3):397-403. [Medline]. [Full Text].

  23. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 1999 Dec. 83(3):389-400. [Medline].

  24. Lagueny A. [Metabolic and nutritional neuropathies]. Rev Prat. 2000 Apr 1. 50(7):731-5. [Medline].

  25. Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care. 2008 Jul. 31(7):1448-54. [Medline]. [Full Text].

  26. Azoulay D, Samuel D, Castaing D, et al. Domino liver transplants for metabolic disorders: experience with familial amyloidotic polyneuropathy. J Am Coll Surg. 1999 Dec. 189(6):584-93. [Medline].

  27. Kaminski HJ, Ruff RL. Neurologic complications of endocrine diseases. Neurol Clin. 1989 Aug. 7(3):489-508. [Medline].

  28. Kluding PM, Pasnoor M, Singh R, D'Silva LJ, Yoo M, Billinger SA, et al. Safety of Aerobic Exercise in People With Diabetic Peripheral Neuropathy. Phys Ther. 2014 Oct 2. [Medline].

  29. Parry GJ. Management of diabetic neuropathy. Am J Med. 1999 Aug 30. 107(2B):27S-33S. [Medline].

Previous
Next
 
Table 1. Symptoms and Signs of Peripheral Neuropathy*
Small-Fiber SensoryLarge-Fiber SensoryAutonomic
Burning painLoss of vibrationHeart rate changes
Cutaneous allodyniaProprioception lossPostural blood pressure change
ParesthesiasLoss of reflexesAbnormal sweating
Lancinating painSlowed NCVsGastroparesis
Loss pain/temperatureSensory ataxiaImpotence
Foot ulcersWeaknessAbnormal ejaculation
Visceral pain loss  
* Modified from Apfel, 1999.[14]
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.